Monday, August 17, 2020 10:39:11 AM
"Who owns the rights on Aviptadil?
Relief owns the patents on Aviptadil that are currently valid in the US and in Europe. In both jurisdictions we have orphan drug status, too."
"Who finances the ongoing trials?
Relief is paying for the trials. NeuroRx conducts the study on our behalf and we cover all the invoices."
"Do you have an agreement with NeuroRx about who receives how much of the profits from Aviptadil? Or is the drug fully owned by Relief?
Aviptadil is our drug.
You are entitled to all revenues it could create?
That is the current situation."
https://themarket.ch/interview/relief-therapeutics-our-drug-could-generate-hundreds-of-millions-of-dollars-per-year-ld.2478
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM